Repligen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Repligen and other ETFs, options, and stocks.

About RGEN

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. 

CEO
Olivier Dominique Loeillot
CEOOlivier Dominique Loeillot
Employees
1,778
Employees1,778
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
1981
Founded1981
Employees
1,778
Employees1,778

RGEN Key Statistics

Market cap
8.56B
Market cap8.56B
Price-Earnings ratio
5.80K
Price-Earnings ratio5.80K
Dividend yield
Dividend yield
Average volume
903.96K
Average volume903.96K
High today
$153.73
High today$153.73
Low today
$146.56
Low today$146.56
Open price
$147.74
Open price$147.74
Volume
258.65K
Volume258.65K
52 Week high
$182.52
52 Week high$182.52
52 Week low
$102.97
52 Week low$102.97

Stock Snapshot

As of today, Repligen(RGEN) shares are valued at $152.07. The company's market cap stands at 8.56B, with a P/E ratio of 5797.67.

As of 2025-11-18, Repligen(RGEN) stock has fluctuated between $146.56 and $153.73. The current price stands at $152.07, placing the stock +3.8% above today's low and -1.1% off the high.

The Repligen(RGEN)'s current trading volume is 258.65K, compared to an average daily volume of 903.96K.

During the past year, Repligen(RGEN) stock moved between $102.97 at its lowest and $182.52 at its peak.

During the past year, Repligen(RGEN) stock moved between $102.97 at its lowest and $182.52 at its peak.

RGEN News

TipRanks 4d
Director’s Multi-Million Dollar Stock Sale Shakes Up Repligen!

New insider activity at Repligen ( (RGEN) ) has taken place on November 14, 2025. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you ma...

Simply Wall St 6d
Repligen's Earnings May Just Be The Starting Point

Even though Repligen Corporation ( ) posted strong earnings, investors appeared to be underwhelmed. We did some digging and actually think they are being unnece...

Repligen's Earnings May Just Be The Starting Point

Analyst ratings

83%

of 23 ratings
Buy
82.6%
Hold
17.4%
Sell
0%

People also own

Based on the portfolios of people who own RGEN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.